A uterine carcinosarcoma, an endometrial carcinosarcoma, and two stage IV colorectal cancers with respective mutations on KRAS and APC, were subjected to drug dose-response screenings with a total of 160 drugs. This evidence concerns the gene KRAS and colorectal cancer.